Crispr Therapeutics is trading at $58.27, +10.01% on August 19, 2026, as biotechnology shares rally after Moderna and Merck reported positive Phase 3 melanoma cancer-vaccine results.
- The trial met its primary recurrence-free-survival endpoint and a key distant-metastasis endpoint.
- No company-specific announcement was identified for August 19, 2026; the move appears primarily sector-driven, with XBI up 3.73% and investors reassessing biotech innovation prospects after Moderna’s breakthrough.